Education
About Us
Working with TipRanks
Follow Us
Telesis Bio, Inc. (TBIO)
:TBIO
TBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.25 - $8.60
Previous CloseN/A
Volume413.00
Average Volume (3M)2.38K
Market Cap
$514.99K
Enterprise Value$49.56M
Total Cash (Recent Filing)$48.06M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.31
Next Earnings
May 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-28.19
Shares Outstanding1,775,839
10 Day Avg. Volume1,697
30 Day Avg. Volume2,377
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.05
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap96.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.92
Enterprise Value/Ebitda-1.80
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Telesis Bio News
PremiumCompany Announcements
Telesis Bio Inc. Faces Financial Challenges Amidst Revenue Decline
PremiumCompany Announcements
Telesis Bio Announces Departure of Chief Legal Officer
---
Ownership Overview
47.05% Insiders
2.62% Other Institutional Investors
50.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TBIO FAQ
What was Telesis Bio, Inc.’s price range in the past 12 months?
Telesis Bio, Inc. lowest stock price was $0.25 and its highest was $8.60 in the past 12 months.
What is Telesis Bio, Inc.’s market cap?
Telesis Bio, Inc.’s market cap is $514.99K.
When is Telesis Bio, Inc.’s upcoming earnings report date?
Telesis Bio, Inc.’s upcoming earnings report date is May 08, 2025 which is in 37 days.
How were Telesis Bio, Inc.’s earnings last quarter?
Currently, no data Available
Is Telesis Bio, Inc. overvalued?
According to Wall Street analysts Telesis Bio, Inc.’s price is currently Overvalued.
Does Telesis Bio, Inc. pay dividends?
Telesis Bio, Inc. does not currently pay dividends.
What is Telesis Bio, Inc.’s EPS estimate?
Telesis Bio, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Telesis Bio, Inc. have?
Telesis Bio, Inc. has 1,775,839 shares outstanding.
What happened to Telesis Bio, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Telesis Bio, Inc.?
Among the largest hedge funds holding Telesis Bio, Inc.’s share is Woodline Partners LP. It holds Telesis Bio, Inc.’s shares valued at 0.
---
Company Description
Telesis Bio, Inc.
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
---
TBIO Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering TBIO
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-91.32%
assigned a buy rating 8 months ago
Copying Steven Mah's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -91.32% per trade.
---